

World Health Organization risk drinking levels as a treatment for alcoholism in
topiramate trials

Alcoholism: Clinical and Experimental Research

45, 1664-1671

DOI: [10.1111/acer.14652](https://doi.org/10.1111/acer.14652)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The Brief Alcohol Use Disorder Severity Scale: An Initial Validation Evaluation. Alcohol and Alcoholism, 0, , .	1.6	1
2	Hazardous drinking and alcohol use disorders. Nature Reviews Disease Primers, 2022, 8, .	30.5	24
3	Combination treatment with varenicline and naltrexone reduces World Health Organization risk drinking levels. Alcoholism: Clinical and Experimental Research, 2022, 46, 2258-2266.	2.4	0
4	A Bayesian meta-analysis of topiramate's effectiveness for individuals with alcohol use disorder. Journal of Psychopharmacology, 2023, 37, 155-163.	4.0	7
5	Motives for nonmedical use of prescription stimulants in community college students. Journal of American College Health, 0, , 1-8.	1.5	0
6	Management of alcohol use disorder in patients with chronic liver disease. Hepatology Communications, 2023, 7, .	4.3	5
7	The Clinical Benefits of Non-abstinent Outcomes in Alcohol Use Disorder Treatment: Evidence from Clinical Trials and Treatment Implications. , 2023, , 341-364.		0